Low dose naltrexone: Harnessing the body's own chemistry to treat human ovarian cancer (News)

The LDN 2021 Conference Recordings Now Available with up to 29 CME Credits [More Details]

Medical Professionals Become an LDN Specialist [More Details]

Submitted by baileylynn_100964 on Mon, 02/08/2021 - 16:08

Low dose naltrexone: Harnessing the body's own chemistry to treat human ovarian cancer

Science Daily
13 July 2011
https://www.sciencedaily.com/releases/2011/07/110712143012.htm

Researchers have discovered that a low dose of the opioid antagonist naltrexone (LDN) markedly suppresses progression of human ovarian cancer transplanted into mice. LDN's antitumor action was comparable to that of chemotherapy (cisplatin, taxol). LDN combined with cisplatin but not taxol had an additive inhibitory action on tumorigenesis. LDN offers a non-toxic and efficacious biologic pathway-related treatment that may benefit patients with this deadly cancer.
 

Type of Video